Cargando…
Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis
BACKGROUND: Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418722/ https://www.ncbi.nlm.nih.gov/pubmed/34482831 http://dx.doi.org/10.1186/s12913-021-06948-6 |
_version_ | 1783748620943622144 |
---|---|
author | Jalkanen, Kari Aarnio, Emma Lavikainen, Piia Lindström, Jaana Peltonen, Markku Laatikainen, Tiina Martikainen, Janne |
author_facet | Jalkanen, Kari Aarnio, Emma Lavikainen, Piia Lindström, Jaana Peltonen, Markku Laatikainen, Tiina Martikainen, Janne |
author_sort | Jalkanen, Kari |
collection | PubMed |
description | BACKGROUND: Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions. METHODS: A decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results. RESULTS: In the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 m€ (95% CI − 185.2 m€ to 717.2 m€) in pharmacy visiting population meaning 1412€ (95% CI − 1024€ to 3967€) expected savings per person. Additionally, 7032 QALYs (95% CI − 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358€ (95% CI − 1397€ to 8431€) using a cost-effectiveness threshold of 50,000 €/QALY. The initial costs were 122.2 m€ with an SROI of 2.09€ (95% CI − 1.52€ to 5.88€). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate. CONCLUSIONS: T2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06948-6. |
format | Online Article Text |
id | pubmed-8418722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84187222021-09-09 Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis Jalkanen, Kari Aarnio, Emma Lavikainen, Piia Lindström, Jaana Peltonen, Markku Laatikainen, Tiina Martikainen, Janne BMC Health Serv Res Research BACKGROUND: Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions. METHODS: A decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results. RESULTS: In the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 m€ (95% CI − 185.2 m€ to 717.2 m€) in pharmacy visiting population meaning 1412€ (95% CI − 1024€ to 3967€) expected savings per person. Additionally, 7032 QALYs (95% CI − 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358€ (95% CI − 1397€ to 8431€) using a cost-effectiveness threshold of 50,000 €/QALY. The initial costs were 122.2 m€ with an SROI of 2.09€ (95% CI − 1.52€ to 5.88€). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate. CONCLUSIONS: T2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06948-6. BioMed Central 2021-09-05 /pmc/articles/PMC8418722/ /pubmed/34482831 http://dx.doi.org/10.1186/s12913-021-06948-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jalkanen, Kari Aarnio, Emma Lavikainen, Piia Lindström, Jaana Peltonen, Markku Laatikainen, Tiina Martikainen, Janne Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title | Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title_full | Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title_fullStr | Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title_full_unstemmed | Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title_short | Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
title_sort | pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418722/ https://www.ncbi.nlm.nih.gov/pubmed/34482831 http://dx.doi.org/10.1186/s12913-021-06948-6 |
work_keys_str_mv | AT jalkanenkari pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT aarnioemma pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT lavikainenpiia pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT lindstromjaana pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT peltonenmarkku pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT laatikainentiina pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis AT martikainenjanne pharmacybasedscreeningtodetectpersonsatelevatedriskoftype2diabetesacostutilityanalysis |